teicoplanin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
glycopeptide antibacterials (Actinoplanes strains)	2998	61036-62-2

Description:

Molecule	Description
Synonyms: teicoplanin Antibiotic 8327A Antibiotic MDL 507 targocid targosid teichomycin	Lipoglycopeptide antibiotic from Actinoplanes teichomyceticus active against gram-positive bacteria. It consists of five major components each with a different fatty acid moiety. Molecular weight: Formula: None CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Molecule

Description

Synonyms:

teicoplanin
Antibiotic 8327A
Antibiotic MDL 507
targocid
targosid
teichomycin

Lipoglycopeptide antibiotic from Actinoplanes teichomyceticus active against gram-positive bacteria. It consists of five major components each with a different fatty acid moiety.

Molecular weight:
Formula: None
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA:
ALOGS:
ROTB: None

Drug dosage:

Dose	Unit	Route
0.40	g	P

ADMET properties:

None

Approvals:

None

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug reaction with eosinophilia and systemic symptoms	205.14	32.23	78	3744	28346	50572956
Thrombocytopenia	82.91	32.23	72	3750	127601	50473701
Acinetobacter infection	74.28	32.23	18	3804	1409	50599893
Stenotrophomonas infection	66.54	32.23	17	3805	1652	50599650
Pyrexia	63.28	32.23	107	3715	380096	50221206
Multiple organ dysfunction syndrome	62.89	32.23	42	3780	50295	50551007
Anaphylactic reaction	62.52	32.23	43	3779	54012	50547290
Septic shock	60.34	32.23	43	3779	57132	50544170
Drug resistance	56.73	32.23	28	3794	18961	50582341
Neutropenia	55.75	32.23	62	3760	147903	50453399
Enterococcal infection	49.90	32.23	19	3803	6879	50594423
Mental status changes postoperative	49.33	32.23	9	3813	174	50601128
Acute generalised exanthematous pustulosis	48.50	32.23	20	3802	8918	50592384
Confusion postoperative	48.40	32.23	9	3813	194	50601108
Haemodynamic instability	47.11	32.23	19	3803	8005	50593297
Cross sensitivity reaction	45.29	32.23	13	3809	1956	50599346
Morganella infection	44.28	32.23	10	3812	575	50600727
Rash maculo-papular	42.62	32.23	26	3796	26615	50574687
Pathogen resistance	42.34	32.23	16	3806	5673	50595629
Haemostasis	40.52	32.23	8	3814	239	50601063
Eosinophilia	39.93	32.23	22	3800	18630	50582672
Renal impairment	37.96	32.23	37	3785	75624	50525678
Bronchopulmonary aspergillosis	37.87	32.23	16	3806	7576	50593726
Klebsiella infection	35.34	32.23	15	3807	7179	50594123
Sepsis	34.23	32.23	46	3776	132879	50468423
Rash macular	33.90	32.23	20	3802	19257	50582045
Folate deficiency	32.32	32.23	10	3812	1945	50599357

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug reaction with eosinophilia and systemic symptoms	126.35	26.38	69	4539	27923	29541996
Pyrexia	93.83	26.38	163	4445	287459	29282460
Cross sensitivity reaction	91.57	26.38	24	4584	1238	29568681
Venoocclusive disease	74.99	26.38	24	4584	2515	29567404
Rash maculo-papular	60.63	26.38	41	4567	24248	29545671
Multiple organ dysfunction syndrome	56.81	26.38	59	4549	63057	29506862
Thrombocytopenia	51.09	26.38	82	4526	134741	29435178
Neutropenia	49.75	26.38	80	4528	131631	29438288
Systemic candida	49.55	26.38	18	4590	2762	29567157
Hyphaema	48.83	26.38	12	4596	476	29569443
Eosinophilia	45.04	26.38	33	4575	22128	29547791
Septic shock	45.00	26.38	52	4556	62508	29507411
Systemic mycosis	37.01	26.38	12	4596	1309	29568610
Fatigue	35.54	26.38	4	4604	316817	29253102
Drug resistance	34.82	26.38	28	4580	21512	29548407
Stevens-Johnson syndrome	34.50	26.38	25	4583	16472	29553447
Acute kidney injury	32.80	26.38	103	4505	265164	29304755
Thrombotic microangiopathy	32.59	26.38	19	4589	8662	29561257
Geotrichum infection	30.06	26.38	8	4600	437	29569482
Coagulation time prolonged	29.91	26.38	10	4598	1200	29568719
Haemophagocytic lymphohistiocytosis	29.25	26.38	19	4589	10485	29559434
C-reactive protein increased	28.83	26.38	35	4573	44228	29525691
Renal impairment	28.73	26.38	48	4560	81285	29488634
Cytomegalovirus infection	27.00	26.38	25	4583	23190	29546729

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug reaction with eosinophilia and systemic symptoms	300.34	23.58	145	8320	54072	64436195
Pyrexia	151.03	23.58	265	8200	558379	63931888
Thrombocytopenia	129.79	23.58	153	8312	223648	64266619
Cross sensitivity reaction	127.34	23.58	37	8428	3330	64486937
Multiple organ dysfunction syndrome	105.42	23.58	95	8370	101318	64388949
Neutropenia	104.24	23.58	142	8323	239482	64250785
Septic shock	100.31	23.58	94	8371	105343	64384924
Rash maculo-papular	99.17	23.58	67	8398	46959	64443308
Acinetobacter infection	88.79	23.58	26	8439	2403	64487864
Anaphylactic reaction	86.87	23.58	72	8393	68592	64421675
Eosinophilia	82.06	23.58	55	8410	38021	64452246
Stenotrophomonas infection	74.45	23.58	24	8441	3056	64487211
Drug resistance	73.95	23.58	50	8415	35052	64455215
Venoocclusive disease	72.24	23.58	25	8440	3960	64486307
Enterococcal infection	58.76	23.58	31	8434	13835	64476432
Fatigue	51.83	23.58	17	8448	748713	63741554
Geotrichum infection	47.99	23.58	13	8452	905	64489362
Sepsis	47.76	23.58	98	8367	230243	64260024
Systemic mycosis	47.69	23.58	16	8449	2307	64487960
Hyphaema	47.36	23.58	12	8453	643	64489624
Renal impairment	46.84	23.58	72	8393	134945	64355322
Acute kidney injury	44.88	23.58	145	8320	449095	64041172
Fungaemia	43.57	23.58	17	8448	3768	64486499
Stevens-Johnson syndrome	43.45	23.58	36	8429	34213	64456054
Toxic skin eruption	41.87	23.58	28	8437	19256	64471011
Pancytopenia	39.65	23.58	69	8396	143240	64347027
Mental status changes postoperative	39.27	23.58	8	8457	158	64490109
C-reactive protein increased	39.25	23.58	55	8410	94854	64395413
Off label use	38.99	23.58	175	8290	632631	63857636
Confusion postoperative	37.55	23.58	8	8457	198	64490069
Acute generalised exanthematous pustulosis	36.90	23.58	23	8442	14035	64476232
Febrile neutropenia	36.72	23.58	78	8387	187579	64302688
Fall	35.59	23.58	6	8459	416820	64073447
Klebsiella infection	35.55	23.58	22	8443	13259	64477008
Haemostasis	35.16	23.58	8	8457	270	64489997
Cholestasis	35.12	23.58	36	8429	44836	64445431
Toxic epidermal necrolysis	35.02	23.58	33	8432	37133	64453134
Morganella infection	33.41	23.58	10	8455	996	64489271
Haemodynamic instability	33.21	23.58	22	8443	14890	64475377
Dizziness	32.96	23.58	8	8457	430155	64060112
Haemophagocytic lymphohistiocytosis	32.19	23.58	23	8442	17586	64472681
Systemic candida	31.70	23.58	15	8450	5314	64484953
Pathogen resistance	31.61	23.58	20	8445	12523	64477744
Pain	29.71	23.58	18	8447	553493	63936774
Thrombotic microangiopathy	28.72	23.58	21	8444	16634	64473633
Fungal infection	27.75	23.58	28	8437	34223	64456044
Mast cell degranulation present	26.65	23.58	5	8460	63	64490204
Staphylococcal infection	26.55	23.58	33	8432	50645	64439622
Coagulation time prolonged	25.98	23.58	10	8455	2136	64488131
Dyspnoea	25.85	23.58	34	8431	718640	63771627
Cytomegalovirus infection	25.82	23.58	28	8437	37171	64453096
Flavobacterium infection	24.88	23.58	5	8460	92	64490175
Pain in extremity	24.48	23.58	5	8460	303080	64187187
Rash erythematous	24.41	23.58	31	8434	48602	64441665
Bronchopulmonary aspergillosis	24.07	23.58	20	8445	19065	64471202

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	J01XA02	ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE OTHER ANTIBACTERIALS Glycopeptide antibacterials
CHEBI has role	CHEBI:33281	antibiotics
CHEBI has role	CHEBI:36047	antibacterial drugs
MeSH PA	D000900	Anti-Bacterial Agents
MeSH PA	D000890	Anti-Infective Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Staphylococcal infectious disease	indication	56038003

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

ID	Source
4025272	VUID
N0000171799	NUI
D02142	KEGG_DRUG
4025272	VANDF
C0145106	UMLSCUI
CHEBI:29687	CHEBI
CHEMBL4297166	ChEMBL_ID
CHEMBL2367892	ChEMBL_ID
D017334	MESH_DESCRIPTOR_UI
DB06149	DRUGBANK_ID
10924	IUPHAR_LIGAND_ID
5155	INN_ID
4U3D3YY81M	UNII
133065662	PUBCHEM_CID
196469	RXNORM
003765	NDDF
387529008	SNOMEDCT_US
96014005	SNOMEDCT_US

Pharmaceutical products:

None